-
Something wrong with this record ?
GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond
B. Vorlova, T. Knedlik, J. Tykvart, J. Konvalinka,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Free Medical Journals
from 1996
ROAD: Directory of Open Access Scholarly Resources
from 1998
PubMed
30844704
Knihovny.cz E-resources
- MeSH
- Adenocarcinoma metabolism MeSH
- Antigens, Surface metabolism MeSH
- Phenotype MeSH
- Glutamate Carboxypeptidase II metabolism MeSH
- Glutamates chemistry MeSH
- Hydrolysis MeSH
- Inflammatory Bowel Diseases metabolism MeSH
- Jejunum metabolism MeSH
- Carboxypeptidases metabolism MeSH
- Rats MeSH
- Aspartic Acid analogs & derivatives chemistry MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Antibodies, Monoclonal chemistry MeSH
- Brain metabolism MeSH
- Mice, Mutant Strains MeSH
- Mice, Transgenic MeSH
- Mice MeSH
- Biomarkers, Tumor metabolism MeSH
- Prostatic Neoplasms metabolism MeSH
- Neuropeptides chemistry MeSH
- Peptide Hydrolases metabolism MeSH
- Intestine, Small metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Glutamate carboxypeptidases II and III (GCPII and GCPIII) are highly homologous di-zinc metallopeptidases belonging to the M28 family. These enzymes are expressed in a variety of tissues, including the brain, prostate, kidney, testis and jejunum. GCPII has been recognized as a neuropeptidase in the central nervous system, as a folate hydrolase participating in absorption of folates in the jejunum and, most importantly, as a prostate-specific membrane antigen that is highly expressed in prostate adenocarcinoma. Furthermore, it has been identified in the neovasculature of most human solid tumors. In contrast, GCPIII has not been associated with any specific physiological function or pathology, and its expression, activity and inhibition have not been as well-studied. In this review, we provide an overview of the current understanding of the structure, enzymatic activity, substrate specificity, and tissue distribution of these two homologous enzymes. We discuss their potential physiological functions and describe the available animal models, including genetically modified mice. We also review the potential use of specific monoclonal antibodies and small-molecule inhibitors recognizing GCPII/III for diagnosis, imaging and experimental therapy of human cancers and other pathologies.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034732
- 003
- CZ-PrNML
- 005
- 20230331111608.0
- 007
- ta
- 008
- 191007s2019 xxu f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)30844704
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vorlova, Barbora $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague, 16610, Czechia.
- 245 10
- $a GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond / $c B. Vorlova, T. Knedlik, J. Tykvart, J. Konvalinka,
- 520 9_
- $a Glutamate carboxypeptidases II and III (GCPII and GCPIII) are highly homologous di-zinc metallopeptidases belonging to the M28 family. These enzymes are expressed in a variety of tissues, including the brain, prostate, kidney, testis and jejunum. GCPII has been recognized as a neuropeptidase in the central nervous system, as a folate hydrolase participating in absorption of folates in the jejunum and, most importantly, as a prostate-specific membrane antigen that is highly expressed in prostate adenocarcinoma. Furthermore, it has been identified in the neovasculature of most human solid tumors. In contrast, GCPIII has not been associated with any specific physiological function or pathology, and its expression, activity and inhibition have not been as well-studied. In this review, we provide an overview of the current understanding of the structure, enzymatic activity, substrate specificity, and tissue distribution of these two homologous enzymes. We discuss their potential physiological functions and describe the available animal models, including genetically modified mice. We also review the potential use of specific monoclonal antibodies and small-molecule inhibitors recognizing GCPII/III for diagnosis, imaging and experimental therapy of human cancers and other pathologies.
- 650 _2
- $a adenokarcinom $x metabolismus $7 D000230
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a monoklonální protilátky $x chemie $7 D000911
- 650 _2
- $a antigeny povrchové $x metabolismus $7 D000954
- 650 _2
- $a kyselina asparagová $x analogy a deriváty $x chemie $7 D001224
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a mozek $x metabolismus $7 D001921
- 650 _2
- $a karboxypeptidasy $x metabolismus $7 D002268
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a glutamátkarboxypeptidasa II $x metabolismus $7 D043425
- 650 _2
- $a glutamáty $x chemie $7 D005971
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrolýza $7 D006868
- 650 _2
- $a idiopatické střevní záněty $x metabolismus $7 D015212
- 650 _2
- $a tenké střevo $x metabolismus $7 D007421
- 650 _2
- $a jejunum $x metabolismus $7 D007583
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a mutantní kmeny myší $7 D008817
- 650 _2
- $a myši transgenní $7 D008822
- 650 _2
- $a neuropeptidy $x chemie $7 D009479
- 650 _2
- $a proteasy $x metabolismus $7 D010447
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a nádory prostaty $x metabolismus $7 D011471
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Knedlik, Tomas $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague, 16610, Czechia.
- 700 1_
- $a Tykvart, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague, 16610, Czechia.
- 700 1_
- $a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague, 16610, Czechia, jan.konvalinka@uochb.cas.cz.
- 773 0_
- $w MED00210602 $t Frontiers in bioscience (Landmark edition) $x 1093-4715 $g Roč. 24, č. - (2019), s. 648-687
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30844704 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20230331111603 $b ABA008
- 999 __
- $a ok $b bmc $g 1451392 $s 1073282
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 24 $c - $d 648-687 $e 20190301 $i 1093-4715 $m Frontiers in bioscience (Landmark edition) $n Front Biosci (Landmark Ed) $x MED00210602
- LZP __
- $a Pubmed-20191007